GeoVax Labs

GeoVax Labs

Biotechnology
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company’s key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

$3.2M

Market Cap • 10/2/2026

1988

(38 years)

Founded

1995

(31 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,8

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,2

EPS

—

Market Cap

Market Cap

3,2M

EV

413,6K

EV/Revenue

0

EV/EBITDA

0

EV/EBIT

0

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-569,6%

Total Yield

-569,6%

Payout

0%

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

1,8%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

33,6%

CAGR Net Income 5Y

33,7%

CAGR OCF 5Y

31,3%

Leverage

N.D./EBITDA

0,1

Debt/Equity

0%

Current Ratio

1,5

Quick Ratio

1,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium